Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Guardant Health, Inc.

< Previous 1 2 3 4 5 Next >
Guardant Health to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health’s Shield Test Selected by Abu Dhabi Department of Health for Blood-Based Colorectal Cancer Screening Program
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health to Present Data at ASCO GI Demonstrating the Value of Its Precision Oncology Tools for Cancer Detection, Treatment Decisions and Therapy Development
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health Receives Medicare Coverage for Guardant Reveal™ on Smart Liquid Biopsy™ Platform for Surveillance Testing in Colorectal Cancer Patients
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health, ConcertAI Collaborate to Form First Data-As-A-Service That Integrates Clinical and Tumor Profiling Data to Accelerate Cancer Therapy Research and Development
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health Announces Preliminary Fourth Quarter and Full Year 2024 Results
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health Shield Platform Selected for Inclusion in National Cancer Institute’s Vanguard Study to Evaluate Emerging Technologies for Multi-Cancer Detection
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Meaningful Insights Biotech Analytics (MiBA) and Guardant Health Announce Strategic Partnership to Optimize Use of Biomarker Testing and Data Analytics to Improve Cancer Care
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health Announces Collaboration With Boehringer Ingelheim to Develop Companion Diagnostic for Detection of Specific Mutations in Advanced Lung Cancer
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health to Share New Research Demonstrating Value of Liquid Biopsy Tests, Real-world Data and AI Analytics in Tailoring Treatment Approaches for Breast Cancer at 2024 San Antonio Breast Cancer Symposium
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue Guidance
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health to Participate in Upcoming Investor Conferences
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health Named to TIME’s List of the Best Inventions of 2024
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health to Share Data Supporting Critical Role of Blood-Based Testing in Colorectal Cancer Screening at ACG 2024
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Roberto A. Mignone Joins Guardant Health Board of Directors
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health to Report Third Quarter 2024 Financial Results on November 6, 2024
From Guardant Health, Inc.
Via Business Wire
Tickers GH
GOZILA Study Published in Nature Medicine Shows Patients With Advanced Cancer Who Receive Liquid Biopsy-Guided Treatment Using Guardant360 CDx Survive Twice as Long
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health to Share Data at ESMO 2024 Further Demonstrating Strong Performance of Its Precision Oncology Technology in Multiple Advanced Tumor Types
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health and Policlinico Gemelli Announce Partnership to Establish A Dedicated In-House Liquid Biopsy Testing Service in Italy
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health to Ring the Nasdaq Opening Bell on August 28 to Celebrate the Launch of Shield™ Blood Test for Colorectal Cancer Screening
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health to Participate in Upcoming Investor Conferences
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health Reports Second Quarter 2024 Financial Results and Increases 2024 Revenue Guidance
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health COSMOS Study Published in Clinical Cancer Research Validates Utility of Guardant Reveal™ Liquid Biopsy Test for Predicting Recurrence in Colorectal Cancer
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health’s FDA-approved Shield™ Blood Test Now Commercially Available in U.S. as a Primary Screening Option for Colorectal Cancer
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health Outcomes Model Confirms the Public Health Importance of Enhanced Colorectal Cancer Screening Outcomes with High Adherence Strategies
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health’s Shield™ Blood Test Approved by FDA as a Primary Screening Option, Clearing Path for Medicare Reimbursement and a New Era of Colorectal Cancer Screening
From Guardant Health, Inc.
Via Business Wire
Tickers GH
Guardant Health to Report Second Quarter 2024 Financial Results on August 7, 2024
From Guardant Health, Inc.
Via Business Wire
Tickers GH
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.